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Aims: Idiopathic/heritable pulmonary arterial hypertension (I/HPAH) carries a poor prognosis despite the thera-
peutic options available. Patient survival from Western countries has been reported, but data from Asia are
scarce.
Main methods:We retrospectively reviewed 56 patients with I/HPAH treated at a single referral center in Japan.
Survival analyses were conducted using the Kaplan–Meier method with the log-rank test. Variables associated
with survival were determined using a Cox proportional hazard model.
Key ﬁndings: There were 41 women (73%) and the mean age at the diagnosis was 32 ± 17 years. Mean survival
time from the diagnosis was 14.9 ± 0.8 years (95% CI, 13.4–16.4 years), with 1-, 2-, 3-, 5- and 10-year
survival rates of 98, 96, 96, 96 and 78%, respectively. In patients who underwent follow-up right-heart
catheterization N3 months after initial catheterization,meanpulmonary arterial pressure (mPAP)was decreased
signiﬁcantly from 63± 15 to 35± 10mmHgwith an improved cardiac index. Patients with high levels of brain
natriuretic peptide (BNP) or low oxygen saturation at baseline showed worse survival. At follow-up, 98% of
patients were on PAH-targeted drugs. WHO functional classes I and II, mPAP b42.5 mm Hg, cardiac index
N2.5 L/min/m2, BNP b52 pg/mL, and 6-min walk distance N347 m at follow-up were predictors of good progno-
sis in the univariate analysis.
Signiﬁcance: The study revealed a long-term survival of Japanese patients with I/HPAH. Hemodynamic parame-
ters improved signiﬁcantly after treatment, which might be related to high prescription rates of PAH-targeted
drugs. Multicenter studies are needed to reveal the prognostic factors for I/HPAH.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/ .0/).3Introduction
Pulmonary arterial hypertension (PAH) has been reported to carry a
poor prognosis despite the therapeutic options available. In the past two
decades, several PAH-targeted drugs have become available. Each PAH-
targeted drug has been reported to improve the prognosis or progres-
sion of PAH (Sitbon et al., 2002; McLaughlin et al., 2005; Rubin et al.,
2011). A treatment algorithm that includes all of these treatment op-
tions is now shown in the guidelines for treatment of pulmonary hyper-
tension (Galie et al., 2009). However, despite all the improvements in
treatment, overall survival has been reported to be unsatisfactory
(Humbert et al., 2010; Lee et al., 2012; Benza et al., 2012).
Although survival analyses of patients with PAH have been reported
fromWestern countries, there is a shortage of data from Asia. A reportl Science, National Hospital
, Kita-ku, Okayama 701-1192,
subara).
. This is an open access article underfrom China demonstrated better survival of patients compared with
previous reports despite the limited treatment options (Zhang et al.,
2011). There is no report from Japan on the survival of patients treated
with PAH-targeted drugs. To elucidate the survival of Japanese patients
with idiopathic pulmonary arterial hypertension/heritable pulmonary
arterial hypertension (I/HPAH), we conducted a retrospective study at
a single center in Japan that deals with referrals for subjects with pul-
monary hypertension.
Materials and methods
Patient selection
We undertook a retrospective review of medical charts on 56
consecutive patients with I/HPAHwho received treatment at the Na-
tional Hospital Organization Okayama Medical Center (Okayama,
Japan) between October 1998 and December 2012. The study protocol
was approved by the Institutional Review Board of our hospital. The di-
agnosis was based on detailed medical history, physical examination,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/ .0/).3
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“incident case”was deﬁned as a patient whowas referred to our hos-
pital in b30 days after diagnostic catheterization, or the initial diagnos-
tic catheterization was conducted at our hospital. All other cases were
considered as “prevalent cases”.
Study protocol
Physical examination, laboratory measurements, 6-minwalk test,
and right-heart catheterization were undertaken before treatment
was initiated. Examinations were conducted repeatedly according
to physical status. The follow-up period for analyses of survival
data ended in March 2013. The end-point for survival analyses was
disease-related death.
Clinical outcomes
Follow-up data were collected when patients achieved the best
values for the mean pulmonary arterial pressure (mPAP) with pre-
served cardiac index. WHO functional class, 6-min walk distance
(6MWD), plasma levels of brain natriuretic peptide (BNP) and uric
acid, hemodynamic parameters [mPAP, right atrial pressure (RAP),
pulmonary capillary wedge pressure, mixed venous oxygen saturation,
cardiac index, and pulmonary vascular resistance (PVR)], heart rate, and
oxygen saturation (SpO2)were compared betweenbaseline and follow-
up. In patients who did not undergo follow-up catheterization, the last
available data (other than hemodynamic data) was evaluated.
Treatments
We also evaluated the treatment received by patients. For survivors,
treatment data were collected when the follow-up data were collected
as described above. For non-survivors, treatment data were collected
at the time when patients received maximum treatment. With regard
to intravenous prostacyclin, all patients received epoprostenol except
for one patient who received treprostinil. We evaluated the maximum
doses of epoprostenol.
Statistical analyses
Results are expressed as themean± standard deviation, unless oth-
erwise speciﬁed. Continuous variableswere compared using t-tests. The
χ2 test was used to assess the signiﬁcance of differences between cate-
gorical variables. WHO functional class is expressed as the median and
number of patients in each class, and changes in WHO functional class
were evaluated using the Wilcoxon signed rank test. Survival analyses
were conducted using the Kaplan–Meier method. Differences between
survival curveswere assessed using the log-rank test. A Cox proportion-
al hazard model was conducted to determine the variables associated
with increased mortality. The hazard ratio (HR) and 95% conﬁdence in-
terval (CI) were deﬁned. To conﬁrm their predictive value, variables
with P b 0.1 were tested in a multivariate model. Receiver operating
characteristic (ROC) curves were constructed to determine an optimal
cutoff value for 6MWD, BNP, mPAP, RAP, cardiac index, and SpO2. All
analyses were undertaken with IBM SPSS Statistics 20 (IBM, Armonk,
NY, USA). Statistical signiﬁcance was deﬁned as P b 0.05.
Results
Baseline characteristics
There were 41 women (73%) and 15 men (27%) in the study. The
mean age was 32 ± 17 years, with a range of 5–69 years at the diag-
nosis. There were 24 incident cases and 32 prevalent cases. Patients
had been treated for 1.4 ± 2.3 years (0.0–8.1 years) at the beginning
of the study. Time between the diagnosis and initiation of treatmentwas 0.4± 2.5 years (−0.1 to 18.9 years). Ninety-six percent of patients
were initiated treatment b1 year after the diagnosis. At the time of diag-
nosis, 11 patientswere inWHO functional class II, 39 in class III, and 6 in
class IV. In 32 prevalent cases, one patient was in WHO functional class
II, 20 in class III, and 11 in class IV at the time of diagnosis. By the time
of referral, one patient improved from class IV to III, 16 patients
remained in the same functional class, and 15 patients' conditions
were deteriorated. Upon referral to our hospital, one patient was in
WHO functional class II, 38 in class III, and 17 in class IV. Hemody-
namic parameters measured at baseline were also evaluated: mPAP
was 61 ± 15 mm Hg, cardiac index was 2.4 ± 0.9 L/min/m2, and
PVR was 1375 ± 611 dyn∙s/cm5.
HPAH and genetic testing
Eight families with 10 patients (18%) with a family history of pul-
monary hypertension were included. Genetic analyses were con-
ducted in 35 patients (including nine cases with HPAH). One patient
with HPAH had not undergone genetic analyses. Four patients from
two families (two patients from each pedigree included in this study)
and two other patients with HPAH from two different families had a
BMPR2 mutation. Of the remaining three patients with HPAH and 26
patients who seemed to be sporadic, no BMPR2 or ALK1 mutation was
detected.
Treatment
All patients, except for one who responded to a calcium channel
blocker, were receiving PAH-targeted drugs: prostacyclin analogs
(n = 52, 93%), endothelin receptor antagonists (n = 38, 68%), and
phosphodiesterase type 5 (PDE5) inhibitors (n = 29, 52%). Intrave-
nous prostacyclin was highly prescribed (n = 43, 77%). Forty-two
patients (75%) were treated with combination therapy. Thirteen pa-
tients (23%) were on warfarin and 53 patients (95%) were on oxygen
therapy.
Overall survival
Seven patients died during the study period: one from alveolar
hemorrhage and six from heart failure. Other than these patients,
two patients were censored: one underwent lung transplantation
and another died in a trafﬁc accident, despite pulmonary hyperten-
sion beingwell controlled. Fig. 1A shows overall survival. Mean survival
time from the diagnosis was 14.9± 0.8 years (95% CI, 13.4–16.4 years),
with 1-, 2-, 3-, 5- and 10-year survival rates of 98, 96, 96, 96 and 78%,
respectively.
Baseline data of survivors and non-survivors
Baseline characteristics of survivors and non-survivors are shown in
Table 1. WHO functional class, 6MWD, BNP, and RAP were signiﬁcantly
worse in non-survivors than in survivors. There was no signiﬁcant dif-
ference in remaining baseline hemodynamic parameters between sur-
vivors and non-survivors. Treatment was also evaluated. There was no
signiﬁcant difference in prescription rate, except for PDE5 inhibitors
and triple PAH-targeted therapy. Non-survivors received PDE5 inhibi-
tors less frequently than survivors (14% vs. 57%, P b 0.05) and none of
the non-survivors received triple therapy.
Follow-up data
At follow-up, WHO functional class, 6MWD, and BNP were signif-
icantly improved (Table 2). Forty-three patients underwent follow-
up right-heart catheterization N3 months after initial catheterization
at our hospital. An average of the time by the follow-up catheterization
evaluated in this study was 3.7 ± 2.8 years (0.1–11.7 years).
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Fig. 1. (A) Mean survival time from the diagnosis was 14.9 ± 0.8 years (95% CI, 13.4–16.4 years), with 1-, 2-, 3-, 5- and 10-year survival rates of 98, 96, 96, 96 and 78%, respec-
tively. (B) Survival rate of patients stratiﬁed by parameters at baseline. a: Survival rate of patients with BNP ≥350 pg/mL at baseline was signiﬁcantly worse than patients with
BNP b350 pg/mL (P b 0.05). b: Survival rate of patients with SpO2≤96% at baseline was signiﬁcantly worse than patients with SpO2 N96% (P b 0.01). (C) Parameters signiﬁcant in
the univariate analysis (a: mPAP, b: WHO functional class (FC), c: cardiac index (CI), d: BNP, e: 6MWD) could be used to stratify the prognosis of patients (P b 0.01).
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Table 1
Clinical and hemodynamic data of survivors and non-survivors at baseline.
Survivor (n = 49) Non-survivor
(n = 7)
P
Age, years 33 ± 18 25 ± 10 0.26
Male, n (%) 14 (29) 1 (14) 0.43
HPAH, n (%) 10 (20) 0 (0) 0.41
WHO functional class (I/II/III/IV) 3 (0/2/34/13) 4 (0/0/2/5) b0.01
6MWD (m) 257 ± 166 103 ± 179 b0.05
BNP (pg/mL) 260 ± 307 705 ± 556 b0.01
Uric acid (mg/dL) 6.3 ± 2.0 6.7 ± 1.0 0.66
mPAP (mm Hg) 61 ± 17 62 ± 14 0.95
RAP (mm Hg) 8 ± 4 13 ± 9 b0.05
PCWP (mm Hg) 9 ± 3 10 ± 5 0.82
SvO2 (%) 66.1 ± 8.7 65.4 ± 10.1 0.86
Cardiac index (L/min/m2) 2.4 ± 0.9 2.4 ± 0.9 0.82
PVR (dyn∙s/cm5) 1391 ± 615 1375 ± 537 0.96
Heart rate (bpm) 74 ± 16 86 ± 15 0.07
SpO2 (%) 97 ± 3 95 ± 3 0.08
Treatment
Oral PGI2 9 (18) 0 (0) 0.22
IV PGI2 37 (76) 6 (86) 0.55
Dose of epoprostenol (ng/kg/min) 79.6 ± 43.2 54.0 ± 47.8 0.19
ERA 34 (69) 4 (57) 0.52
PDE5 inhibitor 28 (57) 1 (14) b0.05
Monotherapy 10 (20) 3 (43) 0.24
Combination therapy 38 (78) 4 (57) 0.24
Number of PAH-targeted drugs: 2 16 (33) 4 (57) 0.21
Number of PAH-targeted drugs: 3 22 (45) 0 (0) b0.05
Warfarin 11 (22) 2 (29) 0.72
Oxygen therapy 46 (94) 7 (100) 0.50
Values other than WHO functional class are expressed as mean ± SD. WHO functional
class is presented as the median and number of patients in each class. HPAH: hereditary
pulmonary arterial hypertension, 6MWD: 6-miute walk distance, BNP: brain natriuretic
peptide, mPAP: mean pulmonary arterial pressure, RAP: right atrial pressure, PCWP: pul-
monary capillary wedge pressure; SvO2: mixed venous oxygen saturation; PVR: pulmo-
nary vascular resistance, SpO2: oxygen saturation, PGI2: prostacyclin; IV: intravenous;
ERA: endothelin receptor antagonist, and PDE5: phosphodiesterase type 5.
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were also signiﬁcantly improved from those at baseline (P b 0.01).
Prognostic factors related to survival
The Cox proportional hazard model was used to estimate the risk
factors for mortality based on the baseline data of patients. Age, sex
or HPAH did not correlate with survival. Whether the patient was
an incident case or prevalent case or time between the diagnosis
and initiation of treatment or study enrollment was not related to
survival. WHO functional class at diagnosis and at referral was not cor-
relatedwith survival. BNP, RAP, and SpO2were important for predicting
the prognosis in the univariate analysis. In the multivariate analysis,Table 2
Clinical and hemodynamic data before and after treatment.
Baseline Follow-up P
Age, years 32 ± 17
WHO functional class (I/II/III/IV) 3 (0/1/38/17) 2 (0/38/15/3) b0.01
6MWD (m) 234 ± 174 378 ± 114 b0.01
BNP (pg/mL) 313 ± 372 67 ± 156 b0.01
Uric acid (mg/dL) 6.4 ± 1.9 6.2 ± 1.7 0.70
mPAP (mm Hg) 63 ± 15 35 ± 10 b0.01
RAP (mm Hg) 8 ± 4 5 ± 4 b0.01
PCWP (mm Hg) 9 ± 3 8 ± 4 0.31
SvO2 (%) 66.2 ± 8.9 77.2 ± 5.7 b0.01
Cardiac index (L/min/m2) 2.3 ± 0.8 3.5 ± 0.9 b0.01
PVR (dyn∙s/cm5) 1473 ± 600 481 ± 421 b0.01
Heart rate (bpm) 76 ± 17 82 ± 18 0.09
SpO2 (%) 97 ± 3 98 ± 3 0.14
Abbreviations are as stated in Table 1. Data were evaluated in 56 patients except for
hemodynamic parameters, that were evaluated in 43 patients who underwent follow-
up right-heart catheterization N3 months after initial catheterization at our hospital.none of the baseline parameters were predictors of survival. ROC
curves were constructed to determine optimal threshold values for
baseline BNP, RAP, and SpO2. The cutoff value for RAP was 10 mm Hg,
but this could not be used to stratify survival. Patients with a BNP
level ≥350 pg/mL and SpO2 ≤96% at baseline had a signiﬁcantly
worse prognosis (Fig. 1B). Patients who died during the study period
did not have any pulmonary diseases. They were severely ill with
overt heart failure at referral and oxygen saturation dropped because
of it.
With regard to follow-up data, WHO functional classes I and II (HR,
0.061; 95% CI, 0.007–0.512; P = 0.01), 6MWD (HR, 0.993; 95% CI,
0.989–0.998; P b 0.01), BNP (HR, 1.003; 95% CI, 1.001–1.005; P b 0.01),
mPAP (HR, 1.101; 95% CI, 1.045–1.161; P b 0.01), RAP (HR, 1.297; 95%
CI, 1.030–1.631; P = 0.03), and cardiac index (HR, 0.027; 95% CI,
0.001–0.650; P = 0.03) were important for predicting the prognosis in
the univariate analysis. Neither PAH-targeted drug was associated with
the prognosis. Based on the area under the curve (AUC) calculated from
the ROC curves, cutoff values were calculated: mPAP (AUC, 0.956; cutoff
value, 42.5 mm Hg), cardiac index (0.904; 2.5 L/min/m2), BNP (0.885;
52 pg/mL), and 6MWD (0.883; 347 m). Cutoff values for these four pa-
rameters andWHO functional classes I and II/III and IVdid stratify survival
(Fig. 1C). However, none of these parameters at follow-upwas a predictor
of survival in the multivariate analysis.
Discussion
The present study is the ﬁrst report on the survival of Japanese
patients with I/HPAH who would have beneﬁtted from recent prog-
ress in the development of PAH-targeted drugs in the modern era.
Each PAH-targeted drug has been reported to improve the prognosis
or progression of PAH (Sitbon et al., 2002; McLaughlin et al., 2005;
Rubin et al., 2011). There have been improvements compared with
those in the National Institutes of Health (NIH) Registry (D'Alonzo
et al., 1991) but overall survival has been reported to be unsatisfactory
despite such improvements in treatment options (Humbert et al., 2010;
Benza et al., 2012; Zhang et al., 2011).
Our data demonstrated that after treatment, hemodynamic parame-
ters improved signiﬁcantly. mPAP decreased signiﬁcantly by 28 mmHg
from 63 ± 15 mm Hg with improved cardiac index. As a result, PVR
was also improved signiﬁcantly. These results are consistent with
our reports showing that epoprostenol and bosentan can reduce
mPAP (Akagi et al., 2008, 2010). The baseline hemodynamic parameters
were comparable or even worse than those reported previously
(Humbert et al., 2010; Lee et al., 2012; Zhang et al., 2011; Badesch
et al., 2010), but the improvementwasmore signiﬁcant. This difference
could have led to a signiﬁcantly better prognosis. None of the baseline
hemodynamic parameters (mPAP, cardiac index, or PVR) was a prog-
nostic factor for survival. This suggests that long-term survival can be
achieved even if severe pulmonary hypertension is conﬁrmed byhemo-
dynamic means (high mPAP and PVR). With regard to follow-up data,
WHO functional classes I and II, mPAP b42.5 mm Hg, cardiac index
N2.5 L/min/m2, BNP b52 pg/mL, and 6MWD N347 m were important
for predicting theprognosis in the present study. A recent study demon-
strated that changes in WHO functional class, cardiac index, SvO2, and
the level of N-terminal-pro BNP on follow-up data would be predictors
of the prognosis (Nickel et al., 2012). In contrast to our study,mPAPwas
not included as a prognostic factor in their study, in which mPAP was
unchanged despite the treatment. Considering that the initial abnor-
mality of I/HPAH is a high mPAP, improvement of the mPAP would
have led to improved survival of this cohort. In another type of pulmo-
nary hypertension, chronic thromboembolic pulmonary hypertension,
mPAP is indeed the determinant of the prognosis (Riedel et al., 1982;
Lewczuk et al., 2001). In I/HPAH, reduction of mPAP might also be an
important determinant for survival, as shown in Fig. 1C-a.
One distinct difference between our cohort and previous cohorts is
the high prescription rate of PAH-targeted drugs. In Japan, there is an
418 A. Ogawa et al. / Life Sciences 118 (2014) 414–419excellent national healthcare system that is supported by the govern-
ment. Currently, PAH is allocated to a special program: the “Speciﬁed
Disease Treatment Research Program”. This program subsidizesmedical
care for patients with rare and intractable diseases. It also enables
Japanese physicians to offer optimal treatment to patients. Epoprostenol
has been reported to be the most potent vasodilator available, but it is
expensive. In previous studies, the prescription rate of epoprostenol
was not high; 0% in the NIH registry, 15% in a French registry, and 23%
(prostanoids; not speciﬁed as epoprostenol) in a study examining the
impact of follow-up data described above (Humbert et al., 2010;
D'Alonzo et al., 1991; Nickel et al., 2012). In our cohort, epoprostenol
was prescribed in 75% of patients. Based on a report stating a reduction
of the mPAP of ≈9 mm Hg by a 1-year treatment with epoprostenol
(Sitbon et al., 2002), the high prescription rate and long-term high
dose of epoprostenol treatment and combination therapy including
epoprostenol could have led to a large reduction in mPAP in our cohort.
Combination therapy has been shown to be beneﬁcial for patients, and
upfront (rather than sequential combination) therapy is expected to
bemore beneﬁcial (Vachiery & Gaine, 2012). However, upfront therapy
is not always possible worldwide because of its high cost. Although a
speciﬁc drug was not associated with the prognosis in the univariate
Cox regression analysis in our cohort, there were signiﬁcant differences
in the prescription rate of PDE5 inhibitors and triple PAH-targeted ther-
apy between survivors and non-survivors. In Japan, PDE5 inhibitors
were approved relatively recently (in 2008). Non-survivors were main-
ly treated before that time, which could be one reason for this
difference.
Another reason for the better overall survival could be a difference in
ethnicity. One report from China showed better survival than that in
Western countries (1- and 3-year survival estimates of 92.1% and
75.1%, respectively) (Zhang et al., 2011). This result is notable because
patients often choose inexpensive medication or abandon treatment
in China. Epoprostenol was not prescribed in this cohort. There might
be a difference in the genetic background between Asians and Cauca-
sians that leads to a different response to treatment.
Estimation of the risk factors for mortality using a univariate Cox
proportional hazard model showed that BNP, RAP, and SpO2 at base-
line were important for the prediction of the prognosis. This result
suggests that patients with I/HPAH cannot be treated successfully
after establishment of severe heart failure, with BNP ≥350 pg/mL
and SpO2 ≤96% even at a referral center. This ﬁnding is consistent
with reports stating that overt heart failure is a potent prognostic
factor. It has also been reported that late referral to a pulmonary hy-
pertension center is related to a delay in appropriate treatment that
ultimately leads to heart failure and is a strong factor for mortality
(Badagliacca et al., 2012).
The goal for treating patients with I/HPAH varies among physicians
and is affected by the healthcare system of each country. Most clinical
trials have set the end-point as an improvement in 6MWD. However,
recently, the improvement of 6MWD has been shown not to be related
to long-term survival (Savarese et al., 2012). In the present study,WHO
functional class, mPAP, cardiac index, BNP, and 6MWD at follow-up
were shown to be important for the prediction of the prognosis in
univariate analysis. No parameters were shown to be signiﬁcant in
the multivariate analysis even though follow-up data (including he-
modynamic parameters) were improved signiﬁcantly compared
with those at baseline. This ﬁndingmight have been because our cohort
was small and the number of events (disease-related death) was too
small. Only seven (13%) subjects died out of all patients. This is a
much lower number compared with those reported previously: 55% in
the NIH registry, 29% in a French registry, and 49% in the study byNickel
et al. (Humbert et al., 2010; D'Alonzo et al., 1991; Nickel et al., 2012).
IPAH was originally reported to occur predominantly in younger
women (D'Alonzo et al., 1991). Recently, it has been reported that in
countries with aging populations, IPAH is diagnosed frequently in elder-
ly patients (Hoeper et al., 2013). However, in the present study, patientswere predominantly young women, similar to that reported in the NIH
registry. Recently, it has also been reported that male patients with PAH
have a worse prognosis (Humbert et al., 2010; Lee et al., 2012; Benza
et al., 2012). However, our results showed thatmale sexwas not a prog-
nostic factor for survival.
This was a single-center retrospective study, so the possibility of
selection bias and survivor bias could not be avoided. Our cohort in-
volved 57% of prevalent cases, and this might be one reason why the
survival seems better than that reported previously. The number of
patients and events was small and there was variation in the
follow-up period. These features could have affected the results of
our study. Amulticenter prospective study with scheduled repetitive
catheterization is needed to conﬁrm the importance of the improve-
ment of hemodynamic data.
Conclusion
The present study revealed long-term survival of Japanese pa-
tients with I/HPAH treated at a single referral center. Patients with
right-heart failure at referral had a poor prognosis. Hemodynamic
parameters were improved signiﬁcantly with treatment despite severe
hemodynamic parameters at baseline. This observation could be related
to the high prescription rates of PAH-targeted drugs in the present
study. Further investigation with a multicenter registry is needed to re-
veal the prognostic factors in Japanese patients with I/HPAH.
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